Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

Phase 4RecruitingNCT07135453

University of Alabama at Birmingham70 enrolled

Overview

The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Vaccine Pneumococcal Disease

Interventions

Pneumococcal VaccineBIOLOGICAL

PCV

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy adult Exclusion Criteria: * No prior history of pneumococcal vaccination * No immunosuppressing medications or chronic diseases that affect immune function

Locations (1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

RECRUITING

Outcomes

Primary Outcomes

Serogroup 33 antibodies

Serum antipneumococcal antibody concentrations (micrograms/mL) against members of serogroup 33, measured using WHO-ELISA

Time frame: 4 weeks post-vaccination

Antibody-mediated killing

Opsonic activity of vaccine-induced antibodies (reported as opsonic index, or OI); measured using an opsonophagocytic killing (OPK) assay.

Time frame: 4 weeks post-vaccination

Central Contacts

David LaFon, MD

CONTACT

2059343411 dlafon@uabmc.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.